Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Cornell C, Khani F, Osunkoya AO, Matoso A, Miyamoto H, Gordetsky JB, et al. Secondary malignancy after urologic reconstruction procedures: a multi-institutional case series. Hum Pathol. 2022;119:69-78.

Boyraz B, Hung YP. Spindle cell tumors of the pleura and the peritoneum: pathologic diagnosis and updates. APMIS. 2022;130(3):140-154.

Rosen DB, Murphy EA, Gejman RS, Capili A, Friedlander RL, Rand S, et al. Cytokine response over the course of COVID-19 infection in pregnant women. Cytokine. 2022;154:155894.

Domingues V, Chock EY, Dufrost V, Risse J, Seshan SV, Barbhaiya M, et al. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev. 2022;21(10):103158.

Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, et al. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. J Clin Oncol. 2022;40(35):4119-4128.

Panarelli NC. In Reply. Arch Pathol Lab Med. 2022;146(10):1182a-1182.

Cai PY, Asad M, Augello MA, Martin L, Louie C, Basourakos SP, et al. A multidisciplinary approach to optimize primary prostate cancer biobanking. Urol Oncol. 2022;40(6):271.e1-271.e7.

Papke DJ, Lindeman NI, Schrag D, J Iorgulescu B. Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2022;31(9):1746-1751.

Cayrol F, Revuelta MV, Debernardi M, Paulazo A, Phillip JM, Zamponi N, et al. Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. Mol Cancer Ther. 2022;21(9):1485-1496.

Buyukozkan M, Alvarez-Mulett S, Racanelli AC, Schmidt F, Batra R, Hoffman KL, et al. Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19. iScience. 2022;25(7):104612.